{
    "clinical_study": {
        "@rank": "63699", 
        "arm_group": [
            {
                "arm_group_label": "faldaprevir(high dose)", 
                "arm_group_type": "Experimental", 
                "description": "10 subjects (approximate sex ration: 1:1) will be assigned to trial by single and multiple dose."
            }, 
            {
                "arm_group_label": "Faldaprevir(low dose)", 
                "arm_group_type": "Experimental", 
                "description": "10 subjects (approximate sex ration: 1:1) will be assigned to trial by single and multiple dose."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the trial is to assess the bioavailability of Faldaprevir soft capsule with\n      single oral dose and multiple oral doses  in Chinese subjects"
        }, 
        "brief_title": "Pharmacokinetics of Faldaprevir of Soft Capsule", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        Healthy male and female subjects\n\n        Exclusion criteria:\n\n        Any relevant deviation from healthy conditionsAny relevant deviation from healthy\n        conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01821937", 
            "org_study_id": "1220.52"
        }, 
        "intervention": [
            {
                "arm_group_label": "faldaprevir(high dose)", 
                "description": "faldaprevir(high dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to high dose treatment in random order", 
                "intervention_name": "faldaprevir(high dose)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Faldaprevir(low dose)", 
                "description": "faldaprevir(low dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to low dose treatment in random order", 
                "intervention_name": "Faldaprevir(low dose)", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "October 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "1220.52.86001 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacokinetics of Single and Multiple Oral Doses of 120 mg and 240 mg BI 201335 in Healthy Chinese Volunteers", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Single dose:AUC,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval  after administration of the first dose)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Single dose:AUC0- (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Single dose:AUCtz- (the percentage of the AUC 0- that is obtained by extrapolation)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Single dose:z (terminal rate constant in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Single dose: t1/2 (terminal half-life of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Single dose: tz (time of last measurable concentration of the analyte in plasma", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Single dose: MRTpo (mean residence time of the analyte in the body after po administration)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Single dose:CL/F (apparent clearance of the analyte in plasma following po administration)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Single dose:Vz/F (apparent volume of distribution during the terminal phase z following an po administration)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Multiple Dose:Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval )", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Multiple Dose:z,ss (terminal rate constant in plasma at steady state)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Multiple Dose: MRTpo,ss (mean residence time of the analyte in the body at steady state after po administration)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Multiple Dose:CL/F,ss (apparent clearance of the analyte in the plasma at steady state following po multiple dose administration)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Multiple Dose:Vz/F,ss (apparent volume of distribution during the terminal phase z at steady state following po administration)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Multiple Dose:Cpre,N (predose concentration of the analyte in plasma immediately before administration of the Nth dose after N-1 doses were administered)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Multiple Dose: tmax(,N) (time from last dosing to maximum concentration of the analyte in plasma after administration of N doses)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Multiple Dose:In addition, the accumulation ratios (RA, Cmax, based on Cmax; RA, AUC, based on AUC0-) and the linearity index (LI) of the analyte in plasma following ten doses in healthy volunteers over a uniform dosing interval  will be calculated.", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Multiple Dose: Cmax,ss(maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval )", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Multiple Dose: AUC,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval )", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Single dose: Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Single Dose:AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable concentration at tz) (if applicable)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Multiple Dose:t1/2,ss (terminal half-life of the analyte in plasma at steady state) (if applicable)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Multiple Dose:tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01821937"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}